ArticleAntimicrobial agents and chemotherapy2010
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
Article in Antimicrobial agents and chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 96 citations in OpenAlex.
- Perioperative rifaximin is not associated with enhanced functional and volumetric recovery after major liver resection.Scientific reports · 2021Trial
- Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial).BMJ open gastroenterology · 2020Trial
- Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.PloS one · 2013Trial
- Harnessing the power of the gut microbiome: a review of supplementation diagnosis and therapy for liver cirrhosis.Cellular and molecular life sciences : CMLS · 2026Review
- SARS-CoV-2 infection and gut-lung axis: the potential role of rifaximin.Inflammopharmacology · 2026Review
- Challenges in the Investigation of Therapeutic Equivalence of Locally Applied/Locally Acting Drugs in the Gastrointestinal Tract: The Rifaximin Case.Pharmaceutics · 2025Review
- Gut microbiota dysbiosis in inflammatory bowel disease: interaction with intestinal barriers and microbiota-targeted treatment options.Frontiers in cellular and infection microbiology · 2025Review
- Rifaximin alleviates irinotecan-induced diarrhea in mice model.Annals of medicine · 2024Article
- Akkermansia muciniphila in the small intestine improves liver fibrosis in a murine liver cirrhosis model.NPJ biofilms and microbiomes · 2024Article
- The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review.Clinical microbiology reviews · 2023Review
- Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy.Antibiotics (Basel, Switzerland) · 2023Review
- Diverticular Disease and Rifaximin: An Evidence-Based Review.Antibiotics (Basel, Switzerland) · 2023Review
- Probing gut-brain links in Alzheimer's disease with rifaximin.Alzheimer's & dementia (New York, N. Y.) · 2022Article
- Microbiome therapeutics for hepatic encephalopathy.Journal of hepatology · 2021Review
- Clinical Management of the Microbiome in Irritable Bowel Syndrome.Journal of the Canadian Association of Gastroenterology · 2021Article
- Effects of Rifaximin on Luminal and Wall-Adhered Gut Commensal Microbiota in Mice.International journal of molecular sciences · 2021Article
- Natural and synthetic antimicrobials reduce adherence of enteroaggregative and enterohemorrhagic Escherichia coli to epithelial cells.PloS one · 2021Article
- Systemic review and network meta-analysis: Prophylactic antibiotic therapy for spontaneous bacterial peritonitis.World journal of hepatology · 2020Article
- Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study.World journal of gastroenterology · 2020Observational
- Efficacy of Aerosolized Rifaximin versus Tobramycin for Treatment of Pseudomonas aeruginosa Pneumonia in Mice.Antimicrobial agents and chemotherapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rifaximin is a poorly absorbed semisynthetic antibiotic derivative of rifampin licensed for use in the treatment of traveler's diarrhea. Rifaximin reduces the symptoms of enteric infection, often without pathogen eradication and with limited effects on intestinal flora. Epithelial cells (HEp-2 [laryngeal], HCT-8 [ileocecal], A549 [lung], and HeLa [cervical]) were pretreated with rifaximin (or control antibiotics) prior to the addition of enteroaggregative Escherichia coli (EAEC). EAEC adherence was significantly reduced following rifaximin pretreatment compared to pretreatment with rifampin or doxycycline for three of the four cell lines tested. The rifaximin-mediated changes to epithelial cells were explored further by testing the attachment and internalization of either Bacillus anthracis or Shigella sonnei into A549 or HeLa cells, respectively. The attachment and internalization of B. anthracis were significantly reduced following rifaximin pretreatment. In contrast, neither the attachment nor the internalization of S. sonnei was affected by rifaximin pretreatment of HeLa cells, suggesting that rifaximin-mediated modulation of host cell physiology affected bacteria utilizing distinct attachment/internalization mechanisms differently. In addition, rifaximin pretreatment of HEp-2 cells led to reduced concentrations of inflammatory cytokines from uninfected cells. The study provides evidence that rifaximin-mediated changes in epithelial cell physiology are associated with changes in bacterial attachment/internalization and reduced inflammatory cytokine release.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.